Rheumatologist | Physician-scientist | Clinical informatician @MayoClinic | Director, Lupus Clinic | Lupus, LN & APS | AI in autoimmune diseases | 🇲🇽in🇺🇸
Mayo Clinic
Joined February 2018
- Tweets1.8K
- Following680
- Followers3.2K
- Likes4.3K
Alí Duarte, MD retweeted
Mayo Clinic in Rochester is again recognized as the #1 Smart Hospital in the world by @Newsweek and Statista on their 2027 World’s Best Smart Hospitals list. rankings.newsweek.com/worlds…
Mayo Clinic Rheumatology just turned 100.
Cortisone. A Nobel Prize. The LE cell. Generations of work that changed the field.
A great symposium, alumni from near and far, and a packed dance floor with the people who make this division what it is.
Here’s to the next 100. 🥂
1/ How common is antiphospholipid syndrome (APS)?
The answer is more complicated than it seems.
In our new Nature Reviews Rheumatology review, we examine why defining the true epidemiologic burden of APS remains challenging.
Full paper here👉: rdcu.be/M2Loes1Gqtia
4/ Takeaway: APS is rare, but estimating how rare is difficult.
We need longitudinal studies with consistent case definitions and better representation of diverse populations to understand its true burden.
5/ Very grateful to my coauthors, especially @ElHasbaniG for his indefatigable interest in APS (and surviving what felt like a million revisions!), and to Karen Schreiber, Ignasi Rodríguez-Pintó, Katrien Devreese & Danieli Andrade.
1/ SLE is not confined to young women. Across 6 CDC-supported, population-based lupus registries (including LUMEN💡)—we examined how SLE incidence varies across demographic groups in diverse U.S. populations.
acrjournals.onlinelibrary.wi…
4/ There were important demographic differences too.
Among women, incidence was highest in Black women aged 20–39. Before age 20, rates were highest among Asian women; after 60, among American Indian/Alaska Native women.
Alí Duarte, MD retweeted
Are some immunosuppressants safer in SLE? In a target trial emulation of 6,168 patients, differences in serious infection risk were initially observed across treatments, but attenuated after accounting for glucocorticoid exposure
A&R
doi.org/10.1002/art.70343
@AliDuarteMD @sandinoReuma @marianagt95
ALT Comparative Safety of Common Immunosuppressant Therapies in Systemic Lupus Erythematosus: A Target Trial Emulation Study. A graphical abstract
1/ Belimumab or anifrolumab for active nonrenal SLE?
There is no head-to-head RCT, so comparative decisions rely on indirect evidence.
Our network meta-analysis led by Marco Martinez and @PaulTejada8 included 11 RCTs and 8,607 patients.
sciencedirect.com/science/ar…
4/ Safety may help break the tie.
Serious adverse events and serious infections were broadly similar.
The clearest difference was herpes zoster, which was more frequent with anifrolumab:
OR 4.74 vs belimumab.
PrEggNut, what a genius name for this study.
Whether a maternal diet rich in eggs and peanuts during pregnancy and lactation can reduce the risk of infants developing food allergies is unclear. Research findings from the PrEggNut trial are summarized in a new Quick Take video. nej.md/4y7Gc1m
ALT Illustration showing a silhouette of a pregnant person with a fetus visible inside, a bowl of peanuts and eggs, and an infant with red rash marks on the skin from a food allergy.
New in @ACR_Journals: Is the infection risk we attribute to an SLE therapy really the drug or partly the glucocorticoid exposure that follows? 🧵
acrjournals.onlinelibrary.wi…
But after incorporating monthly glucocorticoid exposure over follow-up, those differences were attenuated and no longer statistically significant.
So the apparent comparative safety profile changed once steroid exposure over time was considered.